Related Experiment Video

Updated: Jun 4, 2025

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.5K

CDK2-based CDK7 mimic as a tool for structural analysis: Biochemical validation and crystal structure with SY5609

Jana Škerlová1, Veronika Krejčiříková1, Miroslav Peřina2

  • 1Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.

International Journal of Biological Macromolecules
|December 29, 2024
PubMed

Insights

Researchers engineered CDK2m7, a modified CDK2 protein, to mimic CDK7. This novel tool facilitates structure-based drug design for developing new CDK7 inhibitors for cancer therapy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Cyclin-dependent kinases (CDKs) are crucial regulators of cell cycle and transcription.
  • CDK7 is vital for cell division and proliferation, with its gene alterations common in cancer.
  • Targeting CDK7 therapeutically is a promising cancer strategy, yet structure-based drug design has been limited.

Purpose of the Study:

  • To develop a novel protein mimic for CDK7 to enable structure-assisted drug design.
  • To create a reliable and scalable platform for developing CDK7 inhibitors.

Main Methods:

  • Mutagenesis of the CDK2 active site to create a CDK7 mimic (CDK2m7).
  • Production of active CDK2m7-cyclin A2 complex in E. coli.
  • Crystallization of CDK2m7 with a CDK7 inhibitor (SY5609) for structural analysis.

Main Results:

  • CDK2m7 was produced in high yield and purity, forming an active complex with cyclin A2.
  • CDK2m7 demonstrated a shifted inhibitor selectivity towards CDK7 compared to CDK2.
  • The crystal structure of CDK2m7 complexed with SY5609 was determined, showcasing its utility.

Conclusions:

  • CDK2m7 serves as an effective and affordable platform for structure-based rational drug development targeting CDK7.
  • This mimic facilitates the design of novel CDK7 inhibitors for cancer treatment.
Keywords:
Cyclin-dependent kinaseInhibitorSY5609SelectivityStructure-assisted inhibitor designX-ray crystallography

More Related Videos

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk113:15

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1

Published on: February 25, 2016

11.8K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K